Table 1 Baseline demographics
|  | SII ≤ 1449(n = 78) | SII>1449(n = 46) | P |
|---|---|---|---|
Age (years) | 55 (48, 64) | 55 (48, 66) | 0.49 |
Gender, n (%) | Â | Â | 0.23 |
male | 54 (69.2) | 27 (58.7) | Â |
female | 24 (30.8) | 19 (41.3) | Â |
Concomitant disorders, n (%) | Â | Â | Â |
CAD | 2 (2.7) | 3 (6.5) | 0.36 |
Hypertension | 54 (69.2) | 36 (78.3) | 0.28 |
Diabetes | 2 (2.7) | 4 (8.7) | 0.19 |
CKD | 3 (3.8) | 3 (6.5) | 0.67 |
Cerebrovascular disease | 5 (6.4) | 2 (4.3) | 1.00 |
Smoking | 40 (51.3) | 15 (32.6) | 0.04 |
Laboratory results | Â | Â | Â |
D-dimer | 1890 (1200, 3800) | 3650 (1870, 7115) | 0.07 |
 C reactive protein | 69 ± 60 | 109 ± 88 | 0.04 |
PLT(×10*9/L) | 207 ± 82 | 260 ± 79 | 0.01 |
NEUT(×10*9/L) | 7.3 ± 2.5 | 10.7 ± 3.9 | < 0.01 |
LYMPH(×10*9/L) | 1.8 ± 1.2 | 1.2 ± 0.5 | 0.01 |
SII | 885 ± 322 | 2803 ± 2001 | < 0.01 |
Imaging results | Â | Â | Â |
MAD in lesion (mm) | 38 ± 9 | 40 ± 9 | 0.46 |
Debakey III | Â | Â | 0.29 |
IIIa | 16 (20.5) | 6 (13.0) | Â |
IIIb | 62 (79.5) | 40 (87.0) | Â |
FL status | Â | Â | 0.93 |
patent | 27 (34.6) | 17 (37.0) | Â |
partial thrombogenesis | 35 (44.9) | 19 (41.3) | Â |
thrombogenesis | 16 (20.5) | 10 (21.7) | Â |
Oral medication for discharge | Â | Â | Â |
β blocker | 58 (74.3) | 41 (89.1) | < 0.05 |
Alpha blocker | 18 (23.1) | 13 (28.3) | 0.52 |
ACEI/ARB | 61 (78.2) | 34 (73.9) | 0.59 |
CCB | 56 (71.8) | 36 (78.3) | 0.43 |
hydragogue | 26 (33.3) | 11 (23.9) | 0.27 |
statin | 22 (29.2) | 18 (39.1) | 0.21 |